SM
SCMP

Sabby Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Sabby Management’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-33,200
Closed -$349K – 241
2017
Q2 		$349K Sell
33,200
-51,800
-61% -$528K 0.02% 160
2017
Q1 		$935K Buy
85,000
+10,000
+13% +$116K 0.05% 135
2016
Q4 		$1.02M Buy
+75,000
New +$1.05M 0.06% 144

Other funds holding SCMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sabby Management's SCMP Position: Q3 2017 in Review

Sabby Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q3 2017, closing a stake of 33,200 shares — an estimated $349K sold.

Sabby Management first reported a position in SCMP in Q4 2016 and held it in 3 quarters. The position peaked at $1.02M in Q4 2016. 178 funds tracked by Wall St. Rank hold SCMP as of Q3 2017.

  • Sabby Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Sabby Management sold 33,200 Sucampo Pharmaceuticals, Inc. shares in Q3 2017, an estimated $349K.
  • Sabby Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q4 2016 and held it in 3 quarters.
  • Sabby Management's Sucampo Pharmaceuticals, Inc. position peaked at $1.02M in Q4 2016.
  • 178 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.